.Pharmacolibrary.Drugs.ATC.C.C01EB22 .Pharmacolibrary.Drugs.ATC.C.C01EB22| name: | Meldonium | |
| ATC code: | C01EB22 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 0.562 | L |
| clearance: | 0.064 | L/h/kg |
| other parameters in model implementation | ||
Meldonium (also known as mildronate) is a synthetic compound that inhibits carnitine biosynthesis. It was originally developed in Latvia and has been used as a metabolic modulator to treat ischemic heart disease, angina, and myocardial infarction, as well as for enhancing exercise tolerance. It is not FDA-approved in the United States, but has been used clinically in some post-Soviet states. Meldonium became widely known after being banned by WADA for use in athletes from 2016.
Healthy adult volunteers, both sexes, single oral dose.
Knych, HK, et al., & Kass, PH (2017). Pharmacokinetics and pharmacodynamics of meldonium in exercised thoroughbred horses. Drug testing and analysis 9(9) 1392–1399. DOI:10.1002/dta.2214 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28513092